HPLC, UHPLC
Shimadzu launches new inert UHPLC - Nexera XS
Sep 27 2022
Shimadzu, a global leader in analytical instrumentation, has announced the release of the new Nexera XS inert, a bioinert and biocompatible Ultra-High Performance Liquid Chromatograph (UHPLC). The system has been designed to resolve the most common problems encountered in the analysis of biopharmaceuticals, such as the adsorption of target molecules to metal surfaces and corrosion due to mobile phases with high salt content and extreme pH conditions.
The new Nexera XS inert UHPLC features a metal-free sample flow path that prevents unwanted interaction with biopolymers prone to adsorption onto exposed metal sites. By doing this, the Nexera XS inert achieves reduced sample loss and excellent peak shape with reproducibly high sensitivity, high-quality and reliable data. In addition, all wetted surfaces are prepared from corrosion-resistant materials, rendering them stable against mobile phase solvents containing high concentrations of salts or acids.
Nexera XS inert offers the same superior reliability, robustness and expandability as the other UHPLC systems in the Nexera series. It is particularly well-suited to the analysis of biopolymers such as antibodies, peptides and nucleic acid drugs.
All valves used in Nexera XS inert system are designed to inhibit metal adsorption. That ensures worry-free switching between multiple columns for method development or for trap-and-elute analysis without adsorption concerns.
The Nexera XS inert is also equipped with additional new and advanced product features, such as bioinert column switching, tool-free UHPLC connectors and a real-time pH monitor.
For more details visit our website.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Jan 20 2025 Amsterdam, Netherlands
Feb 03 2025 Dubai, UAE
Feb 05 2025 Guangzhou, China
Mar 01 2025 Boston, MA, USA
Mar 04 2025 Berlin, Germany